Joseph Payne, Arcturus CEO
April 20, 2022 10:43 AM EDTUpdated 10:55 AM
R&D
Coronavirus

Arc­turus slides on PhI­II Covid-19 vac­cine da­ta, sig­ni­fy­ing the strug­gle in pro­duc­ing fol­low-up shots

Max Gelman

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

A new dawn for psy­che­delics? Com­pass could be the first to find out

The fate of Mod­er­na’s next-gen Covid shot looms large af­ter a flur­ry of pol­i­cy changes

Weeks af­ter TIG­IT fail, iTeos de­cides to wind down

Up­dat­ed: MD An­der­son-al­lied in­vest­ment firm tar­gets $250M for sec­ond can­cer biotech fund

No­vo Nordisk ‘strong­ly’ urges against phar­ma tar­iffs as com­ments flood in

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times